Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Colorectal cancer (CRC) remains one of the leading causes of cancer-related morbidity and mortality worldwide. Growing evidence suggests that gut microbial dysbiosis plays a crucial role in tumorigenesis and can influence therapeutic responses.
Aim: To explore the associations between serum S100A12 and soluble CD14 (sCD14) levels and gut microbiota alterations in patients with CRC, and to assess the predictive utility of these biomarkers in forecasting chemotherapy response.
Methods: A retrospective analysis was conducted on 104 patients diagnosed with advanced CRC (CRC group) and 104 age-matched and sex-matched healthy controls. Serum concentrations of S100A12 and sCD14 were measured using enzyme-linked immunosorbent assay. Fecal samples collected before chemotherapy were subjected to 16S rRNA sequencing to profile gut microbial composition. Pearson correlation analysis was used to evaluate the relationship between biomarker levels and microbial abundance. Receiver operating characteristic (ROC) curves were used to assess the predictive performance of S100A12 and sCD14 for chemotherapy response.
Results: CRC patients exhibited significantly higher serum levels of S100A12 and sCD14 compared to healthy individuals ( < 0.05). Patients with moderate to severe gut dysbiosis showed the highest elevations of these biomarkers ( < 0.05). Elevated levels of S100A12 and sCD14 were positively correlated with and , and negatively correlated with and ( < 0.05). Both biomarkers significantly decreased following chemotherapy ( < 0.05). Non-responders to chemotherapy had higher pre-treatment levels of S100A12 and sCD14 compared to responders ( < 0.05). Combined ROC analysis showed improved diagnostic accuracy compared to either marker alone.
Conclusion: Serum S100A12 and sCD14 levels are closely associated with gut microbiota imbalance and chemotherapy response in CRC patients. These markers may serve as promising predictive indicators for treatment efficacy and offer potential value in individualized treatment strategies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12362556 | PMC |
| http://dx.doi.org/10.4251/wjgo.v17.i8.108870 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Associations between serum biomarkers and gut microbial imbalance in predicting chemotherapy response in colorectal cancer: A retrospective analysis.
World J Gastrointest Oncol
August 2025
Department of Laboratory Medicine, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou 450003, Henan Province, China.
Background: Colorectal cancer (CRC) remains one of the leading causes of cancer-related morbidity and mortality worldwide. Growing evidence suggests that gut microbial dysbiosis plays a crucial role in tumorigenesis and can influence therapeutic responses.
Aim: To explore the associations between serum S100A12 and soluble CD14 (sCD14) levels and gut microbiota alterations in patients with CRC, and to assess the predictive utility of these biomarkers in forecasting chemotherapy response.
COVID-19 and RA share an SPP1 myeloid pathway that drives PD-L1+ neutrophils and CD14+ monocytes.
JCI Insight
June 2021
Research into Inflammatory Arthritis Centre Versus Arthritis (RACE), University of Glasgow, United Kingdom.
We explored the potential link between chronic inflammatory arthritis and COVID-19 pathogenic and resolving macrophage pathways and their role in COVID-19 pathogenesis. We found that bronchoalveolar lavage fluid (BALF) macrophage clusters FCN1+ and FCN1+SPP1+ predominant in severe COVID-19 were transcriptionally related to synovial tissue macrophage (STM) clusters CD48hiS100A12+ and CD48+SPP1+ that drive rheumatoid arthritis (RA) synovitis. BALF macrophage cluster FABP4+ predominant in healthy lung was transcriptionally related to STM cluster TREM2+ that governs resolution of synovitis in RA remission.
View Article and Find Full Text PDFObjective: Kawasaki disease (KD) is an acute vasculitis of childhood, predominantly affecting the coronary arteries. S100A12, a granulocyte-derived agonist of both the receptor for advanced glycation end products (RAGE) and Toll-like receptor 4 (TLR-4), is strongly up-regulated in KD. This study was undertaken to investigate the potential contributions of S100A12 to the pathogenesis of KD.
View Article and Find Full Text PDFS100A12 facilitates osteoclast differentiation from human monocytes.
PLoS One
March 2019
Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Chuo-ku, Kobe, Japan.
Osteoclasts play a critical role not only in bone homeostasis but also in inflammatory osteolysis, such as that occurring in inflammatory arthritis and systemic inflammation. In both inflammation conditions, inflammatory cytokines like Interleukin (IL)-1, IL-6 and tumor necrosis factor (TNF)-α induce RANKL expression in osteoblasts, but the roles of these cytokines in osteoclast activation remain unclear. S100A12, an S100 family member, is a low-molecular-weight calcium-binding protein.
View Article and Find Full Text PDFSerum Cytokines as Biomarkers in Islet Cell Transplantation for Type 1 Diabetes.
PLoS One
July 2016
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands.
Background: Islet cell transplantation holds a potential cure for type 1 diabetes, but many islet recipients do not reach long-lasting insulin independence. In this exploratory study, we investigated whether serum cytokines, chemokines and adipokines are associated with the clinical outcome of islet transplantation.
Methods: Thirteen islet transplant patients were selected on basis of good graft function (reaching insulin independence) or insufficient engraftment (insulin requiring) from our cohort receiving standardized grafts and immune suppressive therapy.